Sudeep Pharma Shares in Spotlight As Q4 Revenue Grows 15% QoQ to ₹182 Cr

Synopsis: Sudeep Pharma reported a steady Q4 FY26 performance with healthy growth in revenue and profitability on a year-on-year basis. The company posted improved operational performance supported by stable margins and higher demand across pharmaceutical and specialty chemical segments. The company also announced a final dividend of Rs. 1.50 per equity share for FY26. 

Sudeep Pharma Limited is engaged in the manufacturing of pharmaceutical-grade mineral ingredients and specialty chemicals used across pharma, food, nutrition, and industrial applications. The company has built a strong presence in both domestic and export markets through its diversified product portfolio and focus on quality manufacturing. 

The company currently commands a market capitalization of Rs. 7,716 crore, while its shares were trading at Rs. 678 per share up by 1.50% compared to its previous close of Rs. 668. The stock touched a 52-week high of Rs. 796 and a low of Rs. 524. Sudeep Pharma has a stock P/E ratio of 44.7 and a book value of Rs. 78.2 per share. The company reported strong return ratios with ROCE at 28.1 percent and ROE at 25.2 percent. 

Sudeep Pharma reported consolidated revenue of Rs. 182 crore in Q4 FY26, compared to Rs. 172 crore in Q3 FY26 and Rs. 158 crore in Q4 FY25. Revenue increased around 6 percent sequentially and registered nearly 15 percent year-on-year growth, supported by healthy business demand and operational execution. 

Operating profit for the quarter stood at Rs. 63 crore, compared to Rs. 60 crore in Q3 FY26 and Rs. 59 crore in Q4 FY25. The company reported stable operational performance with operating profit growing around 5 percent QoQ and nearly 7 percent YoY. Operating profit margins remained healthy at 34 percent during Q4 FY26. 

Profit before tax came in at Rs. 63 crore in Q4 FY26, compared to Rs. 62 crore in Q3 FY26 and Rs. 58 crore in Q4 FY25. Strong operational efficiency and controlled expenses supported profitability during the quarter. 

Net profit stood at Rs. 49 crore in Q4 FY26 against Rs. 48 crore in Q3 FY26 and Rs. 44 crore in Q4 FY25. Net earnings increased around 2 percent sequentially and nearly 11 percent on a year-on-year basis. Earnings per share (EPS) improved to Rs. 4.33 in Q4 FY26 compared to Rs. 4.20 in Q3 FY26 and Rs. 4.54 in Q4 FY25. 

The Board of Directors recommended a final dividend of Rs. 1.50 per equity share of face value Rs. 1 each for the financial year ended March 31, 2026. The proposed dividend is subject to shareholder approval at the forthcoming Annual General Meeting (AGM). 

Industry Outlook 

India’s pharmaceutical and specialty chemical sectors are expected to witness sustained growth over the coming years, supported by rising healthcare demand, increasing exports, and government-backed manufacturing initiatives. The CRDMO industry alone is expected to double to around Rs. 1.21 lakh crore by 2028, creating significant opportunities for pharmaceutical ingredient manufacturers. 

India also has the largest number of USFDA-compliant plants outside the United States, with over 2,000 WHO-GMP approved facilities. Rising healthcare awareness, increasing global outsourcing, and expansion in specialty healthcare products are expected to drive long-term growth for companies operating in the pharmaceutical ecosystem. 

Sudeep Pharma delivered a healthy Q4 FY26 performance with steady growth in revenue, operating profit, and net earnings. The company continued to maintain strong margins and operational efficiency despite a dynamic business environment. With strong return ratios, stable profitability, expanding pharmaceutical demand, and continued industry tailwinds, Sudeep Pharma appears well-positioned to benefit from long-term opportunities in India’s growing pharmaceutical and specialty chemical markets. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing. 

The post Sudeep Pharma Shares in Spotlight As Q4 Revenue Grows 15% QoQ to ₹182 Cr appeared first on Trade Brains.